These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30447530)

  • 21. Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study.
    Melamed IR; Borte M; Trawnicek L; Kobayashi AL; Kobayashi RH; Knutsen A; Gupta S; Smits W; Pituch-Noworolska A; Strach M; Pulka G; Ochs HD; Moy JN
    Eur J Pharm Sci; 2018 Jun; 118():80-86. PubMed ID: 29522908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
    Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
    J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
    Li Z; Follman K; Freshwater E; Engler F; Yel L
    Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gammaplex
    Wasserman RL
    Immunotherapy; 2017 Oct; 9(13):1071-1088. PubMed ID: 29032734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose.
    Berger M
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141).
    Dash C; Gascoigne E; Gillanders K; Gooi H
    PLoS One; 2015; 10(7):e0131565. PubMed ID: 26222441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
    Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
    PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin.
    Li Z; McCoy B; Engl W; Yel L
    J Clin Immunol; 2021 Aug; 41(6):1331-1338. PubMed ID: 34036490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.
    Costa-Carvalho BT; Sullivan KE; Fontes PM; Aimé-Nobre F; Gonzales IGS; Lima ES; Granato C; de Moraes-Pinto MI
    J Clin Immunol; 2018 Jul; 38(5):628-634. PubMed ID: 30006913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of patients with primary antibody deficiencies in Germany].
    Borte M; Oertelt C; Högy B
    Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
    Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
    Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.
    Frenzel W; Wietek S; Svae TE; Debes A; Svorc D
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):847-855. PubMed ID: 27719744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
    Broyles R; Rodden L; Riley P; Berger M
    Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
    Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
    J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.